1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B4B596BCE8E7FB0D85256FCF0059F578
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/communicating-clinical-study-results-for-maximum-impact?OpenDocument
18
19OpenDocument
203.236.214.224
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25RC




Products & Services

Communicating Clinical Study Results for Maximum Impact

ID: WP-14


Pages: 9


Published: Pre-2016


Delivery Format: Online


 

License Options:


Download White Paper

 

  • STUDY OVERVIEW
  • BENCHMARK CLASS
This white paper is an excerpt from research profiling top pharmaceutical companies that successfully communicate landmark clinical studies findings in ways that boost marketing efforts. Information was gathered through extensive surveys and interviews with executives working in marketing and medical affairs departments. Best Practices, LLC analysts employed qualitative and quantitative research methods to identify and probe the winning strategies and tactics that immortalize study results in the minds of physicians and patients.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic


Companies Profiled:
Abbott; Sanofi-aventis; AstraZeneca; Eli Lilly; GlaxoSmithKline; Merck; Schering-Plough